Dublin, March 19, 2019 (GLOBE NEWSWIRE) -- The "Cancer Vaccines Market - Forecasts from 2019 to 2024" report has been added to ResearchAndMarkets.com's offering.
The global cancer vaccines market is projected to grow at a CAGR of 9.62% to reach US$9.896 billion by 2024, from US$5.704 billion in 2018.
Cancer vaccines are either used to protect against cancer or provide treatment. Hence, they are categorized into two types namely prevention and treatment.
The growing incidences of cancers worldwide are one of the major market drivers driving the growth of the global cancer vaccines market in the forecast period. Cancer Vaccines are approved for Hepatitis B (HBV) and Human Papilloma Virus (HPV) by FDA.
The growing aging population globally may, however, hamper the market growth due to the weak immune system of the elderly population, there are chances where they may be unable to produce an immune response after vaccination.
Major industry players profiled as part of the report are AstraZeneca, GlaxoSmithKline, Merck & Co, Pfizer and Sanofi among others.
Study Coverage
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market.
The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global cancer vaccines value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global cancer vaccines market.
Topics Covered
1. Introduction
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base and Forecast Years Timeline
2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
3. Executive Summary
4. Market Dynamics
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter's Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry In the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. Global Cancer Vaccines Market by Type
5.1. Prevention
5.2. Treatment
6. Global Cancer Vaccines Market by Application
6.1. Cervical Cancer
6.2. Prostate Cancer
6.3. Others
7. Global Cancer Vaccines Market by Geography
7.1. North America
7.1.1. USA
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. Germany
7.3.2. France
7.3.3. United Kingdom
7.3.4. Spain
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. Israel
7.4.3. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. Japan
7.5.3. South Korea
7.5.4. India
7.5.5. Others
8. Competitive Intelligence
8.1. Competition and Offerings Analysis of Key Vendors
8.2. Recent Investment and Deals
8.3. Strategies of Key Players
9. Company Profiles
9.1. Astrazeneca
9.2. Glaxosmithkline Plc.
9.3. Merck & Co., Inc.
9.4. Pfizer Inc.
9.5. Sanofi
9.6. Bristol-Myers Squibb
9.7. Moderna, Inc.
9.8. Oncbiomune Pharmaceuticals Inc.
9.9. Maxivax
9.10. Nouscom
For more information about this report visit https://www.researchandmarkets.com/research/pr7sp8/cancer_vaccines?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.